Cargando…

Enhancer of Zeste Homolog 2 (EZH2) Is a Marker of High-Grade Neuroendocrine Neoplasia in Gastroenteropancreatic and Pulmonary Tract and Predicts Poor Prognosis

SIMPLE SUMMARY: Neuroendocrine neoplasms most frequently arise in the gastroenteropancreatic and pulmonary tract and show an increasing incidence and prevalence. The prognosis and treatment depend on tumor proliferation and clinical behavior. Highly proliferating grade 3 neoplasms especially, show a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bremer, Sebastian C. B., Bittner, Gabi, Elakad, Omar, Dinter, Helen, Gaedcke, Jochen, König, Alexander O., Amanzada, Ahmad, Ellenrieder, Volker, Freiherr von Hammerstein-Equord, Alexander, Ströbel, Philipp, Bohnenberger, Hanibal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221317/ https://www.ncbi.nlm.nih.gov/pubmed/35740494 http://dx.doi.org/10.3390/cancers14122828

Ejemplares similares

Regulation and Therapeutic Targeting of MTHFD2 and EZH2 in KRAS-Mutated Human Pulmonary Adenocarcinoma
por: Li, Yuchan, et al.
Publicado: (2022)

One carbon metabolism in human lung cancer
por: Yao, Sha, et al.
Publicado: (2021)

Expression and prognostic impact of CD49b in human lung cancer
por: Tirilomi, Anna, et al.
Publicado: (2022)

Role of Annexin A1 in Squamous Cell Lung Cancer Progression
por: Elakad, Omar, et al.
Publicado: (2021)

Expression and prognostic impact of DNA-PK in human lung cancer
por: Tirilomi, Anna, et al.
Publicado: (2023)

Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer
por: Elakad, Omar, et al.
Publicado: (2022)

Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer
por: Elakad, Omar, et al.
Publicado: (2020)

Recent advances and conceptual changes in the classification of neuroendocrine tumors of the thymus
por: Bohnenberger, Hanibal, et al.
Publicado: (2021)

Quantitative proteomics identifies biomarkers to distinguish pulmonary from head and neck squamous cell carcinomas by immunohistochemistry
por: Richter, Annika, et al.
Publicado: (2021)

Exploring the Epigenome in Gastroenteropancreatic Neuroendocrine Neoplasias
por: Sharma, Rohini, et al.
Publicado: (2021)

Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas
por: Küffer, Stefan, et al.
Publicado: (2022)

Expression and prognostic impact of alpha thalassemia/mental retardation X-linked and death domain-associated protein in human lung cancer
por: Buentzel, Judith, et al.
Publicado: (2019)

Gastroenteropancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1
por: Tonelli, Francesco, et al.
Publicado: (2012)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated KRAS in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
por: Peng, Luogen, et al.
Publicado: (2023)

Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer
por: Patil, Shilpa, et al.
Publicado: (2021)

Enhancer of Zeste homolog 2 (EZH2) induces epithelial-mesenchymal transition in endometriosis
por: Zhang, Qi, et al.
Publicado: (2017)

Expression of Enhancer of Zeste Homolog 2 (EZH2) Gene in Acute Myeloid Leukemia
por: Hamed, Nahla A. M., et al.
Publicado: (2023)

Preclinical assesement of survivin and XIAP as prognostic biomarkers and therapeutic targets in gastroenteropancreatic neuroendocrine neoplasia
por: Dizdar, Levent, et al.
Publicado: (2016)

Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications
por: Ciarapica, Roberta, et al.
Publicado: (2011)

Enhancer of Zeste Homolog 2 (EZH2) Mediates Glucolipotoxicity-Induced Apoptosis in β-Cells
por: Dahlby, Tina, et al.
Publicado: (2020)

Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy
por: Viol, Fabrice, et al.
Publicado: (2022)

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma
por: Wagener, Nina, et al.
Publicado: (2010)

Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)
por: Changchien, Yi-Che, et al.
Publicado: (2012)

Effects of Enhancer of Zeste Homolog 2 (EZH2) Expression on Brain Glioma Cell Proliferation and Tumorigenesis
por: Cheng, Tianci, et al.
Publicado: (2018)

Osteosyntheseverfahren bei Thoraxwandinstabilität
por: Spering, Christopher, et al.
Publicado: (2020)

Promotion of Glioblastoma Cell Motility by Enhancer of Zeste Homolog 2 (EZH2) Is Mediated by AXL Receptor Kinase
por: Ott, Martina, et al.
Publicado: (2012)

Uropathogenic E.coli (UPEC) Infection Induces Proliferation through Enhancer of Zeste Homologue 2 (EZH2)
por: Ting, Kenneth, et al.
Publicado: (2016)

Downregulation of Enhancer of Zeste Homolog 2 (EZH2) is essential for the Induction of Autophagy and Apoptosis in Colorectal Cancer Cells
por: Yao, Yizhou, et al.
Publicado: (2016)

A systems approach identifies Enhancer of Zeste Homolog 2 (EZH2) as a protective factor in epilepsy
por: Khan, Nadia, et al.
Publicado: (2019)

Silencing the enhancer of zeste homologue 2, Ezh2, represses axon regeneration of dorsal root ganglion neurons
por: Guo, Ting-Ting, et al.
Publicado: (2021)

Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation
por: Fujii, Satoshi, et al.
Publicado: (2008)

Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors
por: Hajósi-Kalcakosz, Szofia, et al.
Publicado: (2012)

Inhibitors of enhancer of zeste homolog 2 (EZH2) activate tumor-suppressor microRNAs in human cancer cells
por: Hibino, S, et al.
Publicado: (2014)

Evaluation of Immunohistochemical Expression of Enhancer of Zeste Homolog 2 (EZH2) and Its Association With Clinicopathological Variables in Carcinoma Cervix
por: Priya, Aditi, et al.
Publicado: (2023)

Gastroenteropancreatic Neuroendocrine Neoplasia Characterization in Portugal: Results from the NETs Study Group of the Portuguese Society of Endocrinology, Diabetes and Metabolism
por: Santos, A. P., et al.
Publicado: (2019)

Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer
por: Conradi, Lena-Christin, et al.
Publicado: (2019)

Advances in the treatment of gastroenteropancreatic neuroendocrine tumors
por: Kunz, Pamela L, et al.
Publicado: (2010)

Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment
por: Díez, Marc, et al.
Publicado: (2013)

Endoscopic Ultrasound in Gastroenteropancreatic Neuroendocrine Tumors
por: Kim, Michelle Kang
Publicado: (2012)

Medical Treatment of Gastroenteropancreatic Neuroendocrine Tumors
por: Rinke, Anja, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_9lksq2hhrc4l3fkjl252qnadtj